Haleon plc — Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for May 2023, dated May 16, 2023. The filing contains a TR-1 notification of a major shareholding change and does not report operating or financial results.
Material ownership change
- GSK plc, through Glaxo Group Limited and related controlled entities, notified Haleon of a disposal of voting rights.
- The threshold was crossed on May 12, 2023; Haleon was notified on May 15, 2023.
- GSK’s reported interest declined from 5.44% to 2.85% of Haleon’s voting rights.
- The resulting position was 262,727,073 Haleon shares, representing 2.85% of voting rights. No financial-instrument exposure was reported.
- The shares are held through Vidacos Nominees Limited as custodian for Glaxo Group Limited.
- The filing states that the disposal was made by Glaxo Group Limited, a wholly owned subsidiary of GSK plc that also holds other external minority interests of the GSK group.
Financial metrics, liquidity, and outlook
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or operational outlook information.
Risks, contingencies, and unusual items
The principal disclosed event is the reduction of GSK’s ownership stake. The filing does not identify litigation, contingencies, unusual charges, or changes to Haleon’s business outlook.
Key facts for investors to verify
- Confirm the final ownership percentage and share count following settlement of the disposal.
- Review any separate notification submitted by GSK plc regarding its own notification obligation.
- Assess whether the reduced GSK stake affects future share disposals, governance, or potential selling pressure.
- Consult Haleon’s financial filings separately for operating performance, leverage, liquidity, and guidance.